Mavenclad (Cladribine) Patent Expiration, LOE Window & CMS Spending
Mavenclad (Cladribine) by Emd Serono: FDA Orange Book LOE 2041-09-10, 2 AB generics, $244.0M 2024 CMS Part D & Medicaid spend, and 42 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Emd Serono |
| FDA Application & Pathway | N022561 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2041-09-10 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 2 |
| 2024 CMS Total Public Spend | $244.0M |
| 2024 Medicare Part D Spend | $178.2M |
| 2024 Medicaid Spend | $65.8M |
| Reported Wholesale Price Change (CA SB 17) | 42 WAC filings (max 21.2% 2-yr change) |